Hledání v detailu akcií
Moje portfolio
Nastavit Oblíbené, nastavit Portfolio
Oblíbené tituly
select
NázevNejlepší
nákup
Nejlepší
prodej
Změna
(%)
ČEZ0,00
KB0,00
PKN67,2967,332,60
Msft-0,47
Nokia3,483,52951,94
IBM1,48
Mercedes-Benz Group AG64,8464,861,38
PFE2,24
25.06.2024 1:38:59
Indexy online
AD Index online
select
AD Index online
 

  • 24.06.2024
Provexis (NTR.L, London)
Závěr k 24.6.2024 Změna (%) Změna (GBP) Objem obchodů (GBP)
0,006 0,00 0,00 6 947
R - Real-Time data si mohou aktivovat klienti Patria Plus / Investor Plus ZDE.

 
  • Poslední aktualizace: 25.06.2024
Popis společnosti
Obecné informace
Název společnostiProvexis plc
TickerPXS
Kmenové akcie:Ordinary Shares
RICPXSP.L
ISINGB00B0923P27
Poslední známé roční výsledky31.03.2023
Poslední známé čtvrtletní výsledky30.09.2023
Počet zaměstnanců k 31.03.2023 2
Akcie v oběhu k 05.04.20242 262 945 255
MěnaGBP
Kontaktní informace
Ulice2 Blagrave Street
MěstoREADING
PSČRG1 1AZ
ZeměUnited Kingdom
Kontatní osoba 
Funkce kontaktní osoby 
Telefon441 753 861 777

Business Summary: Provexis plc is engaged in developing, licensing and selling the proprietary, scientifically proven Fruitflow heart-health functional food ingredient. Fruitflow is a natural extract from tomatoes, which has been shown in human trials to reduce the propensity for aberrant blood clotting, typically associated with cardiovascular disease, which can lead to heart attack and stroke. The extract is available in two formats, a syrup and a spray-dried powder and can be included in a range of food, beverage, and dietary supplement formats. Fruitflow is a highly concentrated form of bioactives that is lycopene-free and contains over 30 known anti-platelet compounds. The syrup and powder versions of Fruitflow are GRAS in the United States. The Company also offers Fruitflow+ Omega-3, a dietary supplement product. The Company sells its Fruitflow+ Omega-3 dietary supplement product direct to consumers and serves its Chinese cross-border e-commerce distributor for this product in China.
Financial Summary: BRIEF: For the six months ended 30 September 2023, Provexis plc revenues increased from L179K to L388K. Net loss increased 71% to L267K. Revenues reflect Fruitflow+omega 3 segment increase of 8% to L89K. Higher net loss reflects Administrative costs - share based payme increase from L11K to L61K (expense), Research and development costs increase of 31% to L140K (expense).
Odvětvová klasifikace
TRBC2012Special Foods & Wellbeing Products
RBSS2004Pharmaceuticals - Generic & Specialty
MGINDUSTRYBiotechnology & Drugs
MGSECTORHealthcare
NAICSMedicinal and Botanical Manufacturing
NAICSResearch and Development in the Physical, Engineering, and Life Sciences (except Nanotechnology and Biotechnology)
NAICSLessors of Nonfinancial Intangible Assets (except Copyrighted Works)
NAICS2007Medicinal & Botanical Mfg
NAICS2007Research and Development in the Physical, Engineering, and Life Sciences (except Biotechnology)
NAICS2007Lessors of Nonfinancial Intangible Assets (except Copyrighted Works)
NAICS1997Medicinal and Botanical Manufacturing
NAICS1997Research and Development in the Physical, Engineering, and Life Sciences
NAICS1997Owners and Lessors of Other Non-Financial Assets
SICMedicinals And Botanicals
SICCommercial Physical Research
SICPatent Owners And Lessors



  • Poslední aktualizace: 25.06.2024
Management společnosti
FunkceJménoVěkVe funkci odVe firmě od
Chief Executive Officer, Executive Director, Company SecretaryIan Ford-19.07.2007
Chief Scientific Officer, Executive DirectorNiamh O'kennedy4912.04.2019